ACADIA Pharmaceuticals Inc. (ACAD) Q1 2026 Earnings Call May 6, 2026 4:30 PM EDT
Company Participants
Albert Kildani – Senior Vice President of Investor Relations & Corporate Communications
Catherine Owen Adams – CEO & Director
Thomas Garner – Executive VP & Chief Commercial Officer
Elizabeth Thompson – Executive VP and Head of Research & Development
Mark Schneyer – Executive VP & CFO
Conference Call Participants
Tessa Romero – JPMorgan Chase & Co, Research Division
Ashwani Verma – UBS Investment Bank, Research Division
Ritu Baral – TD Cowen, Research Division
Brian Abrahams – RBC Capital Markets, Research Division
Tazeen Ahmad – BofA Securities, Research Division
Marc Goodman – Leerink Partners LLC, Research Division
Jack Allen – Robert W. Baird & Co. Incorporated, Research Division
Ami Fadia – Needham & Company, LLC, Research Division
Katherine Delahunt – Morgan Stanley, Research Division
Malcolm Hoffman – BMO Capital Markets Equity Research
Guofang Li – Wolfe Research, LLC
Samuel Beck – Deutsche Bank AG, Research Division
Yatin Suneja – Guggenheim Securities, LLC, Research Division
Julian Hung – Stifel Nicolaus Canada Inc., Research Division
Presentation
Operator
Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your conference operator today. At this time, I would like to welcome everyone to ACADIA Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference over to Albert Kildani, Senior Vice President, Investor Relations and Corporate Development. Please go ahead.
Albert Kildani
Senior Vice President of Investor Relations & Corporate Communications
Good afternoon, and thank you for joining us on today’s call to discuss ACADIA’s first quarter 2026 financial results. Joining me on the call today from ACADIA are Catherine Owen Adams, our Chief Executive Officer, who will provide some opening remarks; followed by Tom Garner, our Chief Commercial Officer, who will discuss our commercial brands, DAYBUE and NUPLAZID. Also joining us today are Elizabeth Thompson, Ph.D, Executive Vice President, Head of Research and
